C Mulatero

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

Sandra M. Swain, David Miles, Sung‐Bae Kim et al. · The Lancet Oncology · 2020 · 898 citations

Medicine, Oncology, Pharmacology +14

Phase III Trial of Vandetanib Compared With Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

Ronald B. Natale, Sumitra Thongprasert, F. Anthony Greco et al. · Journal of Clinical Oncology · 2011 · 296 citations

Medicine, Oncology, Pharmacology +9

Molecular Imaging and Biological Evaluation of HuMV833 Anti-VEGF Antibody: Implications for Trial Design of Antiangiogenic Antibodies

Gordon C. Jayson, Jamal Zweit, Alan Jackson et al. · JNCI Journal of the National Cancer Institute · 2002 · 257 citations · Full text

Medicine, Oncology, Cancer Pharmacology +16

Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC

Edurne Arriola, Matthew Wheater, Ian Galea et al. · Journal of Thoracic Oncology · 2016 · 115 citations · Full text

Medicine, Oncology, Pharmacology +17

The Cochrane collaboration's tool for assessing risk of bias

J Ford, E Cummins, Poonam Sharma et al. · 2013 · 109 citations

Public Health, Biostatistics, Epidemiology +11